VOLUME HAS SPIKED IN ANTICIPATION OF POSITIVE CLINICAL DATA

CATALYST BIOSCIENCES INC CBOE ($CBIO)
CBIO will release at the ISTH conference final Phase 2 data for marzeptaacog alfa in hemophilia.Dr. Johnny Mahlangu, M.D., Professor of haematology, faculty of health sciences, head of the School of Pathology at the University of Witwatersrand in Johannesburg, South Africa, and a principal investigator on the MarzAA Phase 2 study, will deliver an oral presentation on the final data from the Company's next-generation engineered subcutaneous (SQ) coagulation Factor VIIa (FVIIa) marzeptacog alfa (activated) (MarzAA) Phase 2 trial for the treatment of hemophilia A or B with inhibitors. Additionally, the Company will have three posters covering (1) quality of life improvements for subjects in the Phase 2 MarzAA trial, (2) in silico and in vitro immunogenicity risk assessment of its next-generation engineered SQ coagulation Factor IX (FIX), dalcinonacog alfa (DalcA) compared with wildtype FIX and (3) the ongoing Phase 2b study of DalcA.
COMPANY PROFILE

COMPANY PROFILE
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address serious medical conditions. Its pipeline includes hemostasis such as Factor VIIa marzeptacog alfa, Factor IX dalcinonacog alfa, and Factor Xa; and anti-complement. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.